Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Dynamic contrast-enhanced MRI for early evaluation of therapeutic response in pancreatic ductal adenocarcinoma

  • By

  • Martin D. Holland

  • Ezinwanne E. Onuoha

  • Darryl Outlaw

  • Mehmet Akce

  • Midhun Malla

  • Salila Hashmi

  • Sushanth Reddy

  • J. Bart Rose

  • Desiree E. Morgan

  • Grant R. Williams

  • Moh’d Khushman

  • Dana B. Cardin

  • Katherine Frederick-Dyer

  • Xiaoyu Jiang

  • Zarine K. Shah

  • Bassel El-Rayes

  • Junzhong Xu

  • Harrison Kim

  • August 22, 2026

Share

Original Source(s)

Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma

  • by Martin D. Holland, Ezinwanne E. Onuoha, Darryl Outlaw, Mehmet Akce, Midhun Malla, Salila Hashmi, Sushanth Reddy, J. Bart Rose, Desiree E. Morgan, Grant R. Williams, Moh’d Khushman, Dana B. Cardin, Katherine Frederick-Dyer, Xiaoyu Jiang, Zarine K. Shah, Bassel El-Rayes, Junzhong Xu, Harrison Kim

  • August 22, 2026

Related Content

The Cheapest Way to Save a Patient’s Time May Be One We Will Not Pay For

Moving Cancer Survivorship Into Routine Care—Why Are We Still Not Ready for Change?

Correction: Prognostic significance of inflammation-based markers in nasopharyngeal carcinoma: a systematic review and meta-analysis